Continuous hyperfractionated accelerated radiotherapy with/without mitomycin C in head and neck cancer
Werner Dobrowsky, J. Naudé, Joachim Widder et al. · International Journal of Radiation Oncology*Biology*Physics · 1998
Cited by 58 works. doi:10.1016/s0360-3016(98)00321-6
Authors
References
- The hazard of accelerated tumor clonogen repopulation during radiotherapy
- Accelerated fractionation (AF) compared to conventional fractionation (CF) improves loco-regional control in the radiotherapy of advanced head and neck cancers: results of the EORTC 22851 randomized trial
- Measurement of cell kinetics in human tumours in vivo using bromodeoxyuridine incorporation and flow cytometry
- A randomised multicentre trial of CHART versus conventional radiotherapy in head and neck cancer
- Comparison of Conventional and Split-Course Radiotherapy as Primary Treatment in Carcinoma of the Larynx
- Hyperfractionated photon radiation therapy in the treatment of advanced squamous cell carcinoma of the oral cavity, pharynx, larynx, and sinuses, using radiation therapy as the only planned modality: (Preliminary report) by the radiation therapy oncology group (RTOG)
- Radiotherapy with thrice-a-day fractionation in a short overall time: Clinical experiences
- Continuous hyperfractionated accelerated radiotherapy in locally advanced carcinoma of the head and neck region
- Chemotherapy as an adjunct to radiation in the treatment of squamous cell carcinoma of the head and neck: results of the Yale Mitomycin Randomized Trials.
- Activity of mitomycin C for aerobic and hypoxic cells in vitro and in vivo.